采用细胞疗法治疗原发性免疫缺陷疾病患者的 EBV 并发症。
Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders.
机构信息
Center for Cancer and Immunology Research, Children's National Health System, The George Washington University, Washington, DC, United States.
Division of Oncology, Children's National Health System, Washington, DC, United States.
出版信息
Front Immunol. 2018 Mar 19;9:556. doi: 10.3389/fimmu.2018.00556. eCollection 2018.
Abstract
Patients with primary immunodeficiency disorders (PID) have an increased risk from acute and chronic Epstein-Barr Virus (EBV) viral infections and EBV-associated malignancies. Hematopoietic stem cell transplantation (HSCT) is a curative strategy for many patients with PID, but EBV-related complications are common in the immediate post-transplant period due to delayed reconstitution of T cell immunity. Adoptive T cell therapy with EBV-specific T cells is a promising therapeutic strategy for patients with PID both before and after HSCT. Here we review the methods used to manufacture EBV-specific T cells, the clinical outcomes, and the ongoing challenges for future development of the strategy.
摘要
原发性免疫缺陷病（PID）患者发生急性和慢性 EBV（Epstein-Barr Virus）病毒感染和 EBV 相关恶性肿瘤的风险增加。造血干细胞移植（HSCT）是许多 PID 患者的一种根治策略，但由于 T 细胞免疫重建延迟，HSCT 后即刻期 EBV 相关并发症很常见。在 HSCT 前后，使用 EBV 特异性 T 细胞的过继性 T 细胞治疗是 PID 患者有希望的治疗策略。在此，我们综述了 EBV 特异性 T 细胞的制备方法、临床结果以及该策略未来发展所面临的挑战。
相似文献
1
Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders.采用细胞疗法治疗原发性免疫缺陷疾病患者的 EBV 并发症。
Front Immunol. 2018 Mar 19;9:556. doi: 10.3389/fimmu.2018.00556. eCollection 2018.
2
Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.采用 EBV 核抗原 1 特异性 T 细胞过继转移作为异基因干细胞移植后 EBV 再激活和淋巴增殖性疾病的治疗方法。
J Clin Oncol. 2013 Jan 1;31(1):39-48. doi: 10.1200/JCO.2011.39.8495. Epub 2012 Nov 19.
3
Non-uniform Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative Disease.移植后淋巴组织增生性疾病患者接受供者淋巴细胞输注后，EB 病毒特异性 T 细胞呈非均一性扩增。
Front Immunol. 2019 Oct 29;10:2489. doi: 10.3389/fimmu.2019.02489. eCollection 2019.
4
Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.细胞因子诱导的杀伤细胞治疗 EBV 相关恶性淋巴瘤。
Cytotherapy. 2018 Jun;20(6):839-850. doi: 10.1016/j.jcyt.2018.04.005. Epub 2018 May 10.
5
Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.针对造血干细胞移植受者中人类巨细胞病毒、多瘤病毒 BK、爱泼斯坦-巴尔病毒和腺病毒感染的免疫治疗，生成多病毒特异性细胞系中的抗原竞争。
Immunol Lett. 2020 Dec;228:64-69. doi: 10.1016/j.imlet.2020.09.009. Epub 2020 Oct 5.
6
Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.过继性 T 细胞转移治疗异基因干细胞移植后难治性病毒感染的策略。
J Hematol Oncol. 2019 Feb 6;12(1):13. doi: 10.1186/s13045-019-0701-1.
7
Epstein-Barr Virus Smooth Muscle Tumors as Manifestation of Primary Immunodeficiency Disorders.EB 病毒平滑肌肿瘤作为原发性免疫缺陷疾病的表现。
Front Immunol. 2018 Feb 27;9:368. doi: 10.3389/fimmu.2018.00368. eCollection 2018.
8
Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.采用 Epstein-Barr 病毒核抗原 1、3 和裂解抗原 BZLF1 肽池联合刺激，可快速有效地刺激 Epstein-Barr 病毒特异性 T 细胞，用于过继免疫治疗。
Cytotherapy. 2014 Jan;16(1):122-34. doi: 10.1016/j.jcyt.2013.07.008. Epub 2013 Oct 1.
9
Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.在接受异基因造血干细胞移植的患者中，将水痘带状疱疹病毒特异性T细胞添加到巨细胞病毒、爱泼斯坦-巴尔病毒和腺病毒三特异性T细胞中作为过继性免疫疗法。
Cytotherapy. 2015 Oct;17(10):1406-20. doi: 10.1016/j.jcyt.2015.07.005.
10
The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.病毒特异性 CD4+ T 细胞在控制 Epstein-Barr 病毒感染中的作用。
Eur J Cell Biol. 2012 Jan;91(1):31-5. doi: 10.1016/j.ejcb.2011.01.007. Epub 2011 Apr 1.
引用本文的文献
1
Entry into the lytic cycle exposes EBV-infected cells to NK cell killing via upregulation of the MICB ligand for NKG2D and activation of the CD56 and NKG2AKIRCD56 subsets.进入裂解周期会使EB病毒感染的细胞通过上调NKG2D的MICB配体以及激活CD56和NKG2A+KIR+CD56亚群而暴露于自然杀伤细胞的杀伤作用之下。
Front Immunol. 2024 Nov 29;15:1467304. doi: 10.3389/fimmu.2024.1467304. eCollection 2024.
2
Different patterns of failure in two treatment regimens for primary central nervous system lymphoma, a retrospective analysis of 124 cases in Taiwan.两种原发性中枢神经系统淋巴瘤治疗方案的失败模式不同：对台湾 124 例病例的回顾性分析。
Clin Exp Med. 2023 Dec;23(8):5327-5336. doi: 10.1007/s10238-023-01182-2. Epub 2023 Sep 7.
3
The Role of NK Cells in EBV Infection and Related Diseases: Current Understanding and Hints for Novel Therapies.自然杀伤细胞在EB病毒感染及相关疾病中的作用：当前认识与新型治疗策略提示
Cancers (Basel). 2023 Mar 22;15(6):1914. doi: 10.3390/cancers15061914.
4
Updates on Epstein-Barr Virus (EBV)-Associated Nasopharyngeal Carcinoma: Emphasis on the Latent Gene Products of EBV.关于 Epstein-Barr 病毒（EBV）相关的鼻咽癌：重点介绍 EBV 的潜伏基因产物。
Medicina (Kaunas). 2022 Dec 20;59(1):2. doi: 10.3390/medicina59010002.
5
Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities.抗原特异性 T 细胞与 SARS-CoV-2 感染：当前方法与未来可能。
Int J Mol Sci. 2022 Dec 1;23(23):15122. doi: 10.3390/ijms232315122.
6
The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.针对癌症和病毒相关疾病的抗原特异性 T 细胞疗法的产生和应用。
Mol Ther. 2022 Jun 1;30(6):2130-2152. doi: 10.1016/j.ymthe.2022.02.002. Epub 2022 Feb 9.
7
Immunoinformatic Analysis Reveals Antigenic Heterogeneity of Epstein-Barr Virus Is Immune-Driven.免疫信息学分析揭示 EBV 免疫驱动的抗原异质性。
Front Immunol. 2021 Dec 16;12:796379. doi: 10.3389/fimmu.2021.796379. eCollection 2021.
8
Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy.用于过继性细胞治疗的糖皮质激素抵抗型严重急性呼吸综合征冠状病毒2特异性T细胞的产生
Cell Rep. 2021 Jul 20;36(3):109432. doi: 10.1016/j.celrep.2021.109432. Epub 2021 Jul 7.
9
Robust Production of Merkel Cell Polyomavirus Oncogene Specific T Cells From Healthy Donors for Adoptive Transfer.从健康供体中高效生产默克尔细胞多瘤病毒癌基因特异性T细胞用于过继性转移
Front Immunol. 2020 Dec 9;11:592721. doi: 10.3389/fimmu.2020.592721. eCollection 2020.
10
EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.发生于免疫抑制后的 EBV 相关原发性中枢神经系统淋巴瘤是一种独特的免疫生物学实体。
Blood. 2021 Mar 18;137(11):1468-1477. doi: 10.1182/blood.2020008520.
本文引用的文献
1
Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells.使用第三方病毒特异性T细胞对异基因造血干细胞移植后复发性或难治性病毒感染进行长期控制。
Blood Adv. 2017 Nov 2;1(24):2193-2205. doi: 10.1182/bloodadvances.2017010223. eCollection 2017 Nov 14.
2
Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders.原发性免疫缺陷病患者的过继性T细胞免疫疗法
Curr Allergy Asthma Rep. 2017 Jan;17(1):3. doi: 10.1007/s11882-017-0669-2.
3
Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency.遗传性CD70缺陷患者的联合免疫缺陷与爱泼斯坦-巴尔病毒诱导的B细胞恶性肿瘤
J Exp Med. 2017 Jan;214(1):91-106. doi: 10.1084/jem.20160849. Epub 2016 Dec 23.
4
Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.采用病毒特异性T淋巴细胞对原发性免疫缺陷病进行过继性免疫治疗。
J Allergy Clin Immunol. 2016 May;137(5):1498-1505.e1. doi: 10.1016/j.jaci.2015.12.1311. Epub 2016 Feb 24.
5
TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells.TALEN 介导的细胞巨化病毒特异性 T 细胞中糖皮质激素受体的基因失活。
Blood. 2015 Dec 24;126(26):2781-9. doi: 10.1182/blood-2015-08-664755. Epub 2015 Oct 27.
6
Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation.造血干细胞移植后儿童前100天内呼吸道病毒感染导致的显著的移植相关死亡率。
Biol Blood Marrow Transplant. 2015 Oct;21(10):1802-7. doi: 10.1016/j.bbmt.2015.06.015. Epub 2015 Jun 25.
7
The immunology of Epstein-Barr virus-induced disease.EB 病毒诱发疾病的免疫学。
Annu Rev Immunol. 2015;33:787-821. doi: 10.1146/annurev-immunol-032414-112326. Epub 2015 Feb 11.
8
Transplantation outcomes for severe combined immunodeficiency, 2000-2009.2000-2009 年严重联合免疫缺陷的移植结果。
N Engl J Med. 2014 Jul 31;371(5):434-46. doi: 10.1056/NEJMoa1401177.
9
Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.建立并运营一个符合药品生产质量管理规范的同种异体爱泼斯坦-巴尔病毒（EBV）特异性细胞毒性细胞库，用于治疗EBV相关淋巴增殖性疾病。
Br J Haematol. 2014 Nov;167(3):402-10. doi: 10.1111/bjh.13051. Epub 2014 Jul 26.
10
Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.广谱T细胞活性作为异基因造血干细胞移植后腺病毒、EB病毒、巨细胞病毒、BK病毒和人疱疹病毒6型感染的治疗方法。
Sci Transl Med. 2014 Jun 25;6(242):242ra83. doi: 10.1126/scitranslmed.3008825.
Zotero 插件